| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 01/07/2004 | CN1133640C 3'-azido-deoxythymidine-5'-thiopyhosphamino acid ester compound and its preparing process |
| 01/07/2004 | CN1133466C Gelling ophthalmic composition containing xanthan gum |
| 01/07/2004 | CN1133464C Pharmaceutical compositions for controlled release of soluble receptors |
| 01/07/2004 | CN1133456C Liquid medicine for curing beriberi |
| 01/07/2004 | CN1133453C Composite Chinese medicine for treating lung diseases |
| 01/07/2004 | CN1133437C Nocathiacin antibiotics |
| 01/07/2004 | CN1133433C Nucleoside analogs in combination therapy of herpes simplex infections |
| 01/07/2004 | CN1133425C Use of adamantane amines or structurally similar compounds in preparation of medicinal composition |
| 01/07/2004 | CN1133424C Repamycin formulations for oral administration |
| 01/06/2004 | US6673941 Disubstituted imidazoles useful in the treatment of bacterial infections |
| 01/06/2004 | US6673923 Pyrazole antimicrobial agents |
| 01/06/2004 | US6673895 Pro-apoptotic fragments of the dengue virus envelope glycoproteins |
| 01/06/2004 | US6673819 Compounds useful as antibacterial agents |
| 01/06/2004 | US6673793 Oxazinoquinolones useful for the treatment of viral infections |
| 01/06/2004 | US6673791 Non-nucleoside reverse transcriptase inhibitors |
| 01/06/2004 | US6673783 Fusidic acid derivatives |
| 01/06/2004 | US6673780 Such as 4-(4-(3-hydroxy-3-methyl-butane-1-sulfinylmethyl)-phenylmethanesulfinyl)-2 -methyl-butan1-ol for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders |
| 01/06/2004 | US6673777 Guanylhydrazones useful for treating diseases associated with T cell activation |
| 01/06/2004 | US6673379 Use of non-alkalized cocoa solids in a drink |
| 01/06/2004 | US6673375 Mostly comprising sodium metasilicate (pentahydrate) and shows nonspecific immunostimulating activity in plants and animals |
| 01/06/2004 | US6673373 Antifungal formulation and the methods for manufacturing and using the same |
| 01/06/2004 | US6673353 Tuberculosis vaccine |
| 01/06/2004 | US6673349 Crosslinking; forming vaccines |
| 01/06/2004 | CA2285891C Triazole antifungal agents |
| 01/06/2004 | CA2142712C Bordetella bronchiseptica vaccine |
| 01/06/2004 | CA2106895C Combating fish parasites |
| 01/02/2004 | EP1375652A2 Oral compositions for HIV-Infected Subjects |
| 01/02/2004 | EP1375511A2 Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
| 01/02/2004 | EP1375486A1 Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity |
| 01/02/2004 | EP1374910A1 Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection |
| 01/02/2004 | EP1374907A2 Drug transport and delivery system |
| 01/02/2004 | EP1374903A1 Pharmaceutical composition for the prevention of the development and progression of mycotic skin surface diseases |
| 01/02/2004 | EP1374893A1 Vaccination with immuno-isolated cells producing an immunomodulator |
| 01/02/2004 | EP1374892A1 Medicament for the treatment of diseases due to infection by Neisseria Meningitidis |
| 01/02/2004 | EP1374883A1 Nasal spray containing a plant extract for the treatment of diseases such as herpes zoster, hematoma, mastitis and cardiovasculatory weakness |
| 01/02/2004 | EP1374879A1 Bacterial translocation inhibitor and method of inhibiting bacterial translocation |
| 01/02/2004 | EP1374872A1 Pharmaceutical preparations comprising a combination of at least one representative of antibiotics and one of antiphlogistics, process for manufacturing, and use thereof |
| 01/02/2004 | EP1374867A1 Use of chloroquine, hydroxychloroquine and 4 amino-quinolinic derivatives to obtain a drug for the anti retroviral therapy, active towards hiv sensitive strains and towards hiv strains which are resistant to both nucleosidic and non-nucleosidic reverse transcriptase inhibitors and to proteases inhibitors |
| 01/02/2004 | EP1374854A1 Delayed release pharmaceutical composition, method of production and use of said composition |
| 01/02/2004 | EP1373543A2 Method for producing pectin hydrolysis products |
| 01/02/2004 | EP1373537A2 Viral vectors |
| 01/02/2004 | EP1373517A2 Human kinases |
| 01/02/2004 | EP1373513A2 Streptococcus pneumoniae proteins and nucleic acids |
| 01/02/2004 | EP1373511A2 Genes and proteins, and their uses |
| 01/02/2004 | EP1373508A2 Human cytokine receptor |
| 01/02/2004 | EP1373496A1 Methods for identifying peptides which modulate a biological process |
| 01/02/2004 | EP1373478A1 Attenuated live vaccine |
| 01/02/2004 | EP1373477A2 A novel virus (cryptovirus) within the rubulavirus genus and uses therefor |
| 01/02/2004 | EP1373475A2 Immunotherapy based on dendritic cells |
| 01/02/2004 | EP1373319A2 Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders |
| 01/02/2004 | EP1373318A2 Neutralizing human monoclonal antibodies against hiv-1, their production and uses |
| 01/02/2004 | EP1373317A2 Nuclear hormone receptor ligand binding domains |
| 01/02/2004 | EP1373316A2 Nuclear hormone receptor ligand binding domain |
| 01/02/2004 | EP1373315A2 Nuclear hormone receptor ligand binding domain |
| 01/02/2004 | EP1373310A2 Staphylococcus aureus proteins and nucleic acids |
| 01/02/2004 | EP1373308A2 Multimerization of hiv-1 vif protein as a therapeutic target |
| 01/02/2004 | EP1373306A2 Cytoskeletion-associated proteins |
| 01/02/2004 | EP1373298A1 A composition containing novel compound corniculatonin having antifungi properties and a process for preparing the same |
| 01/02/2004 | EP1373289A1 9-amino-14-membered macrolide derived from leucomycin |
| 01/02/2004 | EP1373271A1 Indole derivatives having an inhibitory effect on protein kinases |
| 01/02/2004 | EP1373269A1 Jun kinase inhibitors |
| 01/02/2004 | EP1373267A2 Non-nucleoside reverse transcriptase inhibitors |
| 01/02/2004 | EP1373266A2 (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes |
| 01/02/2004 | EP1373263A1 Heterocyclic compounds for aging-related and diabetic vascular complications |
| 01/02/2004 | EP1373261A2 Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors |
| 01/02/2004 | EP1373258A1 Ether derivatives useful as inhibitors of pde4 isozymes |
| 01/02/2004 | EP1373256A1 Ccr5 antagonists useful for treating aids |
| 01/02/2004 | EP1373250A1 Viologen linked acridine based molecule and process for the preparation thereof |
| 01/02/2004 | EP1373241A1 Method for producing optically active dihydropyrones |
| 01/02/2004 | EP1373240A2 Retinoid x receptor modulators |
| 01/02/2004 | EP1373224A1 New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors |
| 01/02/2004 | EP1373217A1 2-mercapto-4,5-diarylimidazole derivatives and the use thereof as cyclooxygenase inhibitors |
| 01/02/2004 | EP1373211A1 Quinoline derivatives and their use as antibiotics |
| 01/02/2004 | EP1373206A1 Aryl oxime-piperazines useful as ccr5 antagonists |
| 01/02/2004 | EP1373205A1 Novel piperidine derivatives as modulators of chemokine receptors |
| 01/02/2004 | EP1373185A2 Hydrophobic polyamine analogs and methods for their use |
| 01/02/2004 | EP1372735A2 Conjugate of hydroxyalkyl starch and an active agent |
| 01/02/2004 | EP1372733A2 Pharmaceutical compositions of active polypeptides for enhanced pharmacological activity through oral and parenteral administration |
| 01/02/2004 | EP1372730A1 Use of lipoaminoacids as absorption promoters in a pharmaceutical composition |
| 01/02/2004 | EP1372724A2 Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
| 01/02/2004 | EP1372722A1 Method for prophylaxis and treatment of porcine reproductive and respiratory syndrome |
| 01/02/2004 | EP1372714A2 Method for inducing an immune response to polysaccharide bacterial antigens and to protein structures of virus capsids |
| 01/02/2004 | EP1372712A2 Equine herpesvirus vaccine |
| 01/02/2004 | EP1372710A2 Mva expressing modified hiv envelope, gag, and pol genes |
| 01/02/2004 | EP1372709A2 Intimins for the prevention or treatment of infections: i |
| 01/02/2004 | EP1372708A2 Vaccine for transcutaneous immunization |
| 01/02/2004 | EP1372707A1 Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of vibrio cholerae 0139 bound to tetanus toxoid |
| 01/02/2004 | EP1372704A1 Monocyte-specific particulate delivery vehicle |
| 01/02/2004 | EP1372701A2 Methods of therapy for hiv infection |
| 01/02/2004 | EP1372700A1 Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
| 01/02/2004 | EP1372698A2 Use of cytokines of the tgf-beta superfamily for the treatment and diagnosis of skin related disorders |
| 01/02/2004 | EP1372697A2 Use of compounds modulating rxr-ppar heterodimer activity as medicine for treating hepatitis c, and corresponding screening method |
| 01/02/2004 | EP1372695A2 Cell damage inhibitor |
| 01/02/2004 | EP1372675A2 Ionene polymers and their use as antimicrobial agents |
| 01/02/2004 | EP1372672A1 Prophylactic teat treatment |
| 01/02/2004 | EP1372666A1 Use of fluticasone propionate in the treatment of diseases ameliorated by enhancement of epithelial / matrix adhesion such as asthma, cystic fibrosis and influenza |
| 01/02/2004 | EP1372664A1 Use of certain steroids for treatment of blood cell deficiencies |
| 01/02/2004 | EP1372662A1 Taste masked liquid pharmaceutical compositions |
| 01/02/2004 | EP1372659A1 Substances for use in therapy of diseases that are caused by highly proliferative cells |
| 01/02/2004 | EP1372654A2 Quinoline inhibitors of hyak1 and hyak3 kinases |